NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE was delisted on the 10th of May, 2024.
47 hedge funds and large institutions have $36.6M invested in NeuBase Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 12 increasing their positions, 17 reducing their positions, and 11 closing their positions.
24% more call options, than puts
Call options by funds: $147K | Put options by funds: $119K
18% less funds holding
Funds holding: 57 → 47 (-10)
29% less capital invested
Capital invested by funds: $51.4M → $36.6M (-$14.9M)
29% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 17
91% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$301K |
| 2 |
CM
CM Management
Gulf Breeze,
Florida
|
+$287K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$262K |
| 4 |
JAMONY
Jacob Asset Management of New York
Hermosa Beach,
California
|
+$237K |
| 5 |
TAM
Tocqueville Asset Management
New York
|
+$173K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
-$695K |
| 2 |
Millennium Management
New York
|
-$558K |
| 3 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$389K |
| 4 |
Two Sigma Investments
New York
|
-$379K |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$350K |
NBSE Hedge Fund Activity: Q3 2021 in Review
47 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q3 2021, worth a combined $36.6M — down 29% from $51.4M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of NBSE and 1 opened new positions — a net loss of 10 holders — while 17 trimmed existing stakes and 12 added.
The largest buyer was Stonepine Capital Management, adding an estimated $301K. The largest seller was Frontier Wealth Management, exiting entirely with an estimated $695K sold.
- 47 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q3 2021, down from 57 in Q2 2021.
- Funds reported $36.6M of NeuBase Therapeutics, Inc. Common Stock stock for Q3 2021, down 29% quarter-over-quarter.
- 1 fund opened new NeuBase Therapeutics, Inc. Common Stock positions in Q3 2021 and 11 closed out, a net change of -10 holders.
- The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q3 2021 was Stonepine Capital Management, an estimated $301K added.
- The largest NeuBase Therapeutics, Inc. Common Stock seller in Q3 2021 was Frontier Wealth Management, an estimated $695K sold.
Based on aggregated 13F filings for Q3 2021.